Cyramza ® (ramucirumab)

För fullständig produktresumé för Cyramza® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Cyramza® (ramucirumab): Administrering med hjälp av filter

Administrera via infusionspump. En separat infusionsslang med ett proteinbesparande filter med storleken 0,22 mikrometer skall användas och slangen måste spolas med natriumklorid (0,9 %) injektionslösning efter avslutad infusion.

Administration Using a Protein-Sparing Filter

The filter is recommended to remove any possible particles (which include micro-organisms) that may have been inadvertently introduced during the preparation for infusion. Ramucirumab is compatible with a 0.2 micron protein sparing (low protein binding) filter and a 0.2 micron protein sparing (low protein binding) filter of at least 4.2 cm2 surface area may be used for administration.1

Use of the Same Filter

In clinical studies, when ramucirumab was administered in combination with another treatment, the filter was changed between the administration of ramucirumab and the administration of other products.1 Please refer to the local labeling for other products for details on administration.

Administration Using the Same Infusion Line

It is acceptable to use a single/same IV line to administer ramucirumab either before, or after, another medication if the infusion line used is properly flushed with normal saline prior to administering the ramucirumab through the same line.1

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

IV = intravenous

Datum fӧr senaste ӧversyn 2020 M04 17


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss